drugset / Trial / NCT05166304
Rebamipide in Patients With Active Rheumatoid Arthritis
Phase 1/2
Completed
60 enrolled
October 6 University
Minia University · collabSohag University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Although the aetiology of RA remains to be fully elucidated, interleukin (IL)-17 are believed to play a critical role in the pathogenesis of RA. Rebamipide is an antiulcer drug that protects gastric epithelial cells,improves gastric defense mechanisms by increasing gastric mucus. Rebamipide inhibited interleukin (IL)-17, also it inhibits IL-1β-induced RASF proliferation.
Timeline
- Start
- 2024-01-01
- Primary completion
- 2025-08-01
- Completion
- 2025-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rebamipide | Small molecule | 100 mg | Oral |